Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 19, 2008

Kythera Raises $30M to Advance Fat-Reduction Compound

  • Kythera Biopharmaceuticals obtained $40 million in a series C tranched financing round. The company has immediate access to $30 million, and the rest will be available in the first half of 2009.

    Kythera will use the money to finish Phase II trials for its lead product, ATX-101. The compound is being studied in aesthetic and medical indications for the reduction of localized fat deposits. This includes treatment of superficial lipomas, fat deposits in the submental region of the face/neck, and localized fat deposits in other parts of the body.

    The funding was led by new investor Jafco and included BBT Capital Management/Apothecary Capital, PFM, Versant Ventures, Arch Venture Partners, Prospect Venture Partners, Altitude Life Science Ventures, and Wilson Sonsini Goodrich & Rosati.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »